scholarly journals Invasive fungal infections in pediatric bone marrow transplant recipients: single center experience of 10 years

2000 ◽  
Vol 26 (9) ◽  
pp. 999-1004 ◽  
Author(s):  
L Hovi ◽  
UM Saarinen-Pihkala ◽  
K Vettenranta ◽  
H Saxen
1988 ◽  
Vol 22 (10) ◽  
pp. 769-772 ◽  
Author(s):  
John D. Cleary ◽  
Daniel Weisdorf ◽  
Courtney V. Fletcher

Our objective was to prospectively study febrile and chill reactions associated with two amphotericin B (AB) infusion rates, slow (2-hour) versus rapid (45 minute). Seventeen consenting bone marrow transplant recipients in whom AB was to be initiated for documented or suspected fungal infections were recruited. After standardized premedication, patients received eight daily AB infusions (0.5 mg/kg/d, concentration 0.25 mg/ml). Rate was assigned using a randomized, crossover pair design. Axillary temperature, chills, and meperidine dose required to resolve chills were monitored for each infusion. For the first pair of infusions, fever (defined as a rise of 1 °C) occurred frequently, in 12 of 17 (70.5 percent) and 13 of 17 patients (76.4 percent), with a mean rise of 1.7 °C (range 1.1–3.7) and 1.7 °C (1.1–3.5) degrees for the 45-minute and 2-hour infusions, respectively (p > 0.10). Chills were observed in 15 of 17 (88.2 percent) and 14 of 17 (82.3 percent) recipients of the 45-minute and 2-hour infusions, respectively. The time of onset (p > 0.10) and the duration of chills (p = 0.08) were similar for both infusion rates. Meperidine requirements for rapid and slow infusions were similar as well (p = 0.12). These data suggest that for patients free of preexisting renal and cardiac disease, rapid AB infusions are well tolerated and produce adverse reactions (fever and chills) similar in nature and severity to slower infusions.


2003 ◽  
Vol 9 (3) ◽  
pp. 238-242 ◽  
Author(s):  
Hideki Mitsui ◽  
Takahiro Karasuno ◽  
Taisuke Santo ◽  
Kentaro Fukushima ◽  
Hitomi Matsunaga ◽  
...  

2018 ◽  
Vol 24 (3) ◽  
pp. S422
Author(s):  
Dharma Choudhary ◽  
Divya Doval ◽  
Sanjeev Sharma ◽  
Vipin Khandelwal ◽  
Rasika Setia ◽  
...  

2015 ◽  
Vol 20 (1) ◽  
pp. 17-23 ◽  
Author(s):  
Lyn Tucker ◽  
Tara Higgins ◽  
Eric F. Egelund ◽  
Baiming Zou ◽  
Vini Vijayan ◽  
...  

OBJECTIVES: The primary objective of this study was to determine the optimal daily dose of voriconazole required to achieve therapeutic trough concentrations in children 1 month to 18 years of age. The secondary objective was to analyze the association between voriconazole trough concentrations and clinical and microbiological outcomes, toxicity, and mortality. METHODS: This study was a retrospective chart review (October 2009 to August 2012) of pediatric oncology/bone marrow transplant patients with proven or probable invasive fungal infections treated with intravenous or oral voriconazole. Patients were excluded if they were older than 18 years of age, had no voriconazole concentrations drawn during the study period, or received voriconazole prior to the study period. RESULTS: Thirty-four patients were reviewed; 11 patients met all criteria for inclusion. There were 6 males and 5 females, with a median age of 8 years (range: 0.8–14.8) and a median weight of 27 kg (range: 9–74). Doses were adjusted to a median 6 mg/kg/dose (range: 3–8.7 mg/kg/dose) given every 8 (n = 5) to 12 (n = 6) hours; dose regimens varied greatly. All but 1 child achieved a voriconazole trough concentration above 1 mg/L; 7 children had a trough concentration above 2 mg/L. The median time to achieve a therapeutic trough concentration was 11 days (range: 6–37 days). Therapy failed for 4 of 11 patients, including 3 of the 4 youngest patients (p=0.022). Three of the 4 for whom therapy failed also had voriconazole trough concentrations less than 2 mg/L; this did not reach statistical significance. Voriconazole therapy was discontinued in 2 patients due to toxicity. CONCLUSIONS: This study confirmed that voriconazole pharmacokinetics vary greatly in pediatric oncology/bone marrow transplant patients. “Optimal” doses varied over nearly a 3-fold range. Younger patients may be at greater risk of poor outcomes and may require additional monitoring and dose adjustment.


Sign in / Sign up

Export Citation Format

Share Document